MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint In Phase 2 Trial With 63% Responder Rate At 12 Weeks 79% Responder Rate At 6 Months In Open-Label ...

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in o ...